CVS Health Corp. 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by CVS Health Corporation on May 14, 2026. The filing was submitted on May 18, 2026. The meeting addressed corporate governance matters, including the election of directors, ratification of auditors, executive compensation, and the approval of a new incentive compensation plan.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A quorum was established with 1,142,802,406 shares present. The following matters were voted upon:
- Director Elections: All 13 nominees were elected to the Board of Directors for one-year terms. Vote counts varied by nominee, with "For" votes ranging from approximately 940 million to 1.02 billion.
- Auditor Ratification: The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 was approved.
- Executive Compensation: The advisory proposal to approve the compensation of named executive officers was approved.
- Incentive Compensation Plan: Stockholders approved the 2026 Incentive Compensation Plan (2026 ICP), which replaces the expiring 2017 plan. The 2026 ICP applies to awards granted after May 14, 2026.
- Stockholder Proposal: A stockholder proposal to reduce the threshold for the right to act by written consent was not approved.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. It references the Proxy Statement filed on April 3, 2026, for detailed descriptions of the proposals and the terms of the 2026 ICP.
Key Facts for Investor Verification
- Verify the specific terms and share limits of the newly approved 2026 Incentive Compensation Plan in the referenced Proxy Statement.
- Review the voting breakdown for directors receiving significant "Against" votes (e.g., Michael F. Mahoney received approximately 96 million "Against" votes).
- Confirm the details of the rejected stockholder proposal regarding written consent thresholds to understand potential future governance activism.
- Check the April 3, 2026 Proxy Statement for the full text of the 2026 ICP and executive compensation disclosures.